Jupiter Neurosciences EBIT

The latest EBIT for JUNS is $-9M as of March 2026. That compares with $-3.1M in the prior-year period — down 186.9% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Jupiter Neurosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, JUNS's EBIT moved from $-3.1M to $-9M — a 186.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jupiter Neurosciences's operating scale or balance-sheet position.

Against its sector companies, JUNS currently prints $-9M for EBIT, while the sector average sits near $-63M. That is roughly 85.6% above the sector mean. Large gaps often invite a closer look at Jupiter Neurosciences's growth, margins, and balance sheet.

A EBIT figure of $-9M for JUNS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting JUNS's EBIT ($-9M), review year-over-year change from $-3.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.